Novasenta employs a patient-centric discovery process that focuses on the in-depth analysis of high-quality samples from human tumors. By mapping the tumor microenvironment (TME) and leveraging the intersection of biology and computation, the company aims to identify novel, therapeutically relevant targets for cancer treatment. Their unique approach to target discovery is driven by a world-class team and is supported by high-dimensional single-cell transcriptomic datasets generated in collaboration with UPMC. This data is analyzed through a proprietary computational data mining platform that extracts biological insights, characterizes distinct cell subtypes within the TME, and identifies immune networks that influence the anti-tumor immune response.

At the heart of Novasenta's discovery platform are two proprietary computational programs designed for systematic and scalable cancer target identification. These programs foster collaboration between biologists and computational teams, enhancing the efficiency of the discovery process. Once potential targets are prioritized, Novasenta employs a comprehensive suite of in vitro and in vivo assays, including CRISPR gene editing technology, to validate these targets. This adaptable platform allows for the exploration of cancer targets across various cell types in the TME, ultimately leading to the development of a pipeline of therapeutics aimed at novel immune cell targets, representing the next generation of immuno-oncology drug candidates.

United States

Novasenta discovers novel therapeutic targets to develop innovative and effective treatments with the goal of transforming the lives of patients with cancer

Novasenta

Company Details